# Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis

> **NCT04807972** · PHASE1 · TERMINATED · sponsor: **AbbVie** · enrollment: 40 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** ABBV-927
- **DRUG:** Budiglimab
- **DRUG:** modified FOLFIRINOX

## Key facts

- **NCT ID:** NCT04807972
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-28
- **Primary completion:** 2024-03-25
- **Final completion:** 2024-03-25
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Strategic considerations
- **Last updated:** 2025-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04807972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04807972, "Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04807972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*